Expression of E-cadherin, beta-catenin and topoisomerase IIalpha in leiomyosarcomas.
BACKGROUND
The expression of E-cadherin, beta-catenin and topoisomerase II has been associated with clinical outcome of several cancers including sarcomas. We aimed to evaluate the expression of these markers in leiomyosarcomas (LMS).


METHODS
Paraffin blocks of 19 primary, nonmetastatic LMS were analysed immunohistochemically for the expression of the above-mentioned markers with a cutoff level for positivity of 20% of cell staining.


RESULTS
Expression of E-cadherin was negative in all LMS. Nuclear expression of beta-catenin was also negative in all cases, while positive cytoplasmic beta-catenin expression was observed in approximately half of the patients. The majority of LMS had expression of topoisomerase IIalpha, although only in 10 patients was this expression in more than 20% of tumour cells. From the analysed factors, tumour size was statistically significantly correlated with relapse-free survival.


CONCLUSIONS
Further evidence with larger series is required in order to determine the implication of these markers in LMS.
Gogou
Pinelopi N
PN
Department of Radiotherapy, University of Ioannina, Medical School, Ioannnina, Greece.
Batistatou
Anna
A
Pakos
Emilios E
EE
Apostolikas
Nikiforos
N
Stefanou
Dimitrios
D
Tsekeris
Pericles G
PG
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000378:metabolism*; D015820:Cadherins / Q000378:metabolism*; D004250:DNA Topoisomerases, Type II / Q000378:metabolism*; D004268:DNA-Binding Proteins / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007890:Leiomyosarcoma / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D051176:beta Catenin / Q000378:metabolism*
D000951:Antigens, Neoplasm; D015820:Cadherins; D004268:DNA-Binding Proteins; D051176:beta Catenin; D004250:DNA Topoisomerases, Type II